Back
Speaker illustration

undefined undefined undefined

Presentations

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Event: ESC Congress 2022

Topic: Health Economics

Session: Costs and cost-effectiveness

Access
Like
Thumbnail

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 1

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources